Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.32 |
| ▸ | PPARA | Q07869 | 2/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25062385 | 0.96 | ALOX5 (0.36) | CYP3A4HTTSMN1; SMN2SMYD2ALOX5 | |
| SCHEMBL31528877 | 0.95 | CYP3A4 (0.35) | CYP3A4HTTSMN1; SMN2SMYD2ALOX5 | |
| SCHEMBL31528924 | 0.95 | CYP3A4 (0.35) | CYP3A4HTTSMN1; SMN2SMYD2ALOX5 | |
| SCHEMBL31528857 | 0.95 | CYP3A4 (0.35) | CYP3A4HTTSMN1; SMN2SMYD2ALOX5 | |
| SCHEMBL21801968 | 0.92 | HTT (0.38) | CYP3A4HTTSMN1; SMN2NPC1SMYD2 | |
| SCHEMBL4271454 | 0.82 | SMYD2 (0.38) | CYP3A4HTTSMN1; SMN2SMYD2PPARA | |
| SCHEMBL12192743 | 0.82 | ALDH1A1 (0.40) | CYP3A4HTTSMN1; SMN2TSHRMAPK1 | |
| SCHEMBL26100458 | 0.81 | LMNA (0.42) | CYP3A4HTTSMN1; SMN2LMNATSHR | |
| SCHEMBL26100784 | 0.81 | SMYD2 (0.38) | CYP3A4HTTSMN1; SMN2LMNASMYD2 | |
| SCHEMBL12921004 | 0.81 | SMYD2 (0.42) | CYP3A4HTTSMN1; SMN2SMYD2PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020065312-A1 | Aminotetralins as 5-HT1Dalpha agonists | SCHAUS JOHN M (US) | 2002-05-30 | — | — | US | disclosed |
| US-6355674-B1 | PSYCHOLOGICAL DISORDERS; ANTISEROTONINE AGENTS | ELI LILLY AND COMPANY | 2002-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065312-A1 | Aminotetralins as 5-HT1Dalpha agonists | HTR1D, HTR1A, HTR1E | CYP3A4 1747/4885HTT 389/4885SMN1; SMN2 2763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.